STOCK TITAN

Treace Medical Concepts, Inc. - TMCI STOCK NEWS

Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.

Overview of Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc. is a commercial-stage medical device company specializing in advanced foot and ankle surgical solutions. With a primary focus on 3D bunion correction and the treatment of complex midfoot deformities, the company harnesses breakthrough technologies to improve surgical practices and patient outcomes. Its innovative Lapiplasty 3D Bunion Correction procedure is designed to address the root cause of bunion deformities by correcting misalignments in all three planes, setting a new benchmark in surgical care for bunion patients.

Core Business and Technological Innovation

At its core, Treace Medical Concepts operates within the high-growth niche of orthopaedic medical devices. The company designs, manufactures, and markets a range of products that include sophisticated instruments, implants, and surgical techniques aimed at reproducibly correcting bunion and midfoot deformities. Its patented procedures signify a significant evolution in musculoskeletal correction by incorporating 3D surgical methodologies. This approach not only accentuates precision and reproducibility but also facilitates faster patient recovery and reduced post-operative complications.

Market Position and Value Proposition

Treace is strategically positioned within a market valued in the billion-dollar range, where the demand for improved surgical interventions is constant. The company extracts value from its innovative product portfolio by providing surgeons with instrumented systems that enhance the standard of care in bunion and midfoot correction. This is achieved through an innovation-driven, high-velocity approach that upholds ethical and high-quality standards—a commitment that resonates well with the company’s core mission of enhancing patient care while managing healthcare costs effectively.

Operational Excellence and Industry Impact

Operating as a single business segment, Treace Medical Concepts integrates research, design, manufacturing, and marketing under a unified strategy. Its operations are geared towards ensuring that each device and technique offers reproducible, high-quality outcomes. The company’s diverse product suite, which includes not only the flagship Lapiplasty system but also complementary systems such as the Adductoplasty Midfoot Correction and SpeedPlate Rapid Compression Implants, exemplifies its comprehensive approach. These innovations empower foot and ankle surgeons to achieve consistent surgical outcomes, making the company a pivotal entity in the transformation of orthopaedic surgery.

Commitment to Quality and Ethical Standards

Embedded in the company’s operational ethos is a commitment to the highest standards of ethical conduct and clinical excellence. Treace Medical Concepts is dedicated not only to advancing surgical technology but also to ensuring that every procedural improvement translates into better patient experiences and reduced long-term healthcare costs. Its robust portfolio of clinical studies and ongoing research efforts provide a critical evidence base that reinforces the efficacy and safety of its procedural innovations.

Understanding the Product Suite

The Lapiplasty 3D Bunion Correction System represents a quantum leap in bunion surgery by systematically addressing the true underlying anatomical misalignments. This system is complemented by other instrumented solutions designed for minimally invasive correction, broadening the spectrum of surgical options available to practitioners. These products underscore the company’s philosophy of integrating advanced technology with rigorous clinical validation to transform the standard of care in orthopaedic procedures.

Competitive Landscape and Surgical Community Engagement

Within a competitive market landscape, Treace distinguishes itself through its sole focus on surgical correction of bunion and related midfoot deformities. Unlike competitors that rely on conventional methods, Treace’s emphasis on complete 3D correction offers a reproducible and scalable solution. The company actively engages with the surgical community through conferences, clinical presentations, and training events, thereby reinforcing its technical authority and contributing to knowledge sharing in the field.

Concluding Insights

Treace Medical Concepts, Inc. embodies the intersection of clinical innovation and operational excellence, contributing substantively to the evolution of foot and ankle surgical practices. Its methodical approach to product development and ethical operational standards makes it a reliable source of transformative surgical technology. For professionals seeking detailed insights into advanced orthopaedic solutions, the company’s offerings provide a comprehensive overview of modern procedural innovations grounded in proven clinical methodologies.

Rhea-AI Summary
Treace Medical Concepts, Inc. reported strong financial results for Q4 2023 and full-year 2023, with revenue increasing by 25% and 32% respectively. The company's gross margin remained robust at 81.6% in Q4 2023. Treace also saw a significant increase in active surgeons and direct sales representatives. The company's patent portfolio expanded, and it initiated commercialization of new technologies. Despite a net loss, Treace provided optimistic guidance for 2024, expecting revenue growth of 18-20% and improved Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
-
Rhea-AI Summary
Treace Medical Concepts, Inc. will release financial results for the fourth quarter and full year of 2023 after the close of trading on Tuesday, February 27, 2024. The company will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. A live and archived webcast of the event and investor presentation will be available on the Company’s investor relations website. Treace routinely posts important information for investors in the 'Investor Relations' section of its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.26%
Tags
conferences earnings
-
Rhea-AI Summary
Treace Medical Concepts, Inc. announces positive three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions. The study demonstrated consistent, positive radiographic and patient-reported outcomes maintained at three years, early return to weight bearing, low radiographic recurrence rates, reduction in pain, and significant improvement in patient-reported quality of life measures. Interim data from the Company’s Mini3D™ prospective, multicenter study also showed favorable clinical and patient-reported outcomes with a mini-incision approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
Rhea-AI Summary
Treace Medical Concepts, Inc. announces the full commercial release of its Micro-Lapiplasty™ System and limited clinical release of its Mini-Adductoplasty™ System and RedPoint™ Patient-Specific Instrumentation. The company will highlight new technology innovations and three-year interim ALIGN3D™ clinical results at the 2024 American College of Foot and Ankle Surgeons Annual Scientific Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time. Preliminary unaudited fourth quarter and full-year 2023 revenue results show a significant increase, with revenue of $61.8 million to $62.2 million in the fourth quarter of 2023, an approximate 25% increase at the midpoint over the same period in 2022, and revenue of $186.7 million to $187.1 million for the full-year 2023, an approximate increase of 32% at the midpoint compared to the prior year. Blended average revenue per Lapiplasty® procedure kit sold in the fourth quarter of 2023 was approximately $6,437, a record high and 9% increase over the same period in 2022. The company also saw substantial new active surgeon additions and a 35% increase in direct quota carrying sales representatives over year-end 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
none
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) to present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 3:45 pm Pacific Time. The CEO will discuss the company's flagship Lapiplasty® and Adductoplasty® Procedures. The webcast and replay will be available on the investor relations website. Treace routinely posts important information for investors on its website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.24%
Tags
conferences
Rhea-AI Summary
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) reported a 23% increase in revenue to $40.8 million for the third quarter of 2023. The company also achieved a 36% year-to-date increase in revenue. The gross margin was 80.4% in the third quarter, and 81.0% year to date. Treace has expanded its patent portfolio to 52 granted U.S. patents, with additional patents worldwide and pending U.S. patent applications. The CEO, John T. Treace, highlighted a 21% increase in the surgeon base and a record blended average selling price of $6,311.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.9%
Tags
-
Rhea-AI Summary
Treace Medical Concepts, Inc. (TMCI) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on November 14, 2023. The CEO and CFO will discuss the Lapiplasty® 3D Bunion Correction® Procedure. A live webcast and replay will be available on the investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
-
Rhea-AI Summary
Treace Medical Concepts, Inc. will present new interim data for the ALIGN3D™ clinical study at the AOFAS Annual Meeting. The data shows early return to weight bearing in 8.4 days, low recurrence rate, and 81% reduction in pain. The company also highlights new product innovations, including the SpeedPlate™ and Micro-Lapiplasty™ technologies. Full commercial launch of these technologies is expected in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
Rhea-AI Summary
Treace Medical Concepts, Inc. announces forthcoming issuance of U.S. Patent No. 11,771,467 for bunion correction procedure
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.89%
Tags
none

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

The current stock price of Treace Medical Concepts (TMCI) is $6.76 as of April 15, 2025.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately 421.7M.

What is the core focus of Treace Medical Concepts, Inc.?

Treace Medical Concepts, Inc. specializes in the design, manufacture, and marketing of advanced surgical devices for correcting bunion and related midfoot deformities using 3D correction methodologies.

How does the Lapiplasty 3D Bunion Correction procedure work?

The procedure is designed to correct bunion deformities in all three planes by addressing the underlying anatomical misalignments, thereby restoring joint stability and enabling a reproducible surgical outcome.

What products are included in Treace's portfolio?

The company's portfolio includes the flagship Lapiplasty system, the Adductoplasty Midfoot Correction System, and the SpeedPlate Rapid Compression Implants among other instrumented surgical solutions.

Who are the primary customers for Treace Medical Concepts’ products?

The primary customers include foot and ankle surgeons, orthopedic physicians, ambulatory surgery centers, and hospitals aiming to improve surgical outcomes for bunion and midfoot deformities.

How does Treace differentiate itself from competitors?

Treace differentiates itself by focusing exclusively on 3D surgical correction for bunions, offering a comprehensive suite of innovative, reproducible instrumented systems that set new standards in the industry.

What is the significance of Treace's innovation-driven approach?

Their approach ensures that every product is developed with a focus on clinical evidence and reproducibility, which helps enhance surgical outcomes, reduce complications, and improve overall patient care.

How does Treace support the surgical community?

Treace engages with the surgical community through conferences, clinical studies, and training events, providing updated research findings and technical insights that assist surgeons in adopting advanced surgical methods.
Treace Medical Concepts, Inc.

Nasdaq:TMCI

TMCI Rankings

TMCI Stock Data

421.72M
45.63M
26.04%
60.61%
4.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA